A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Asthma
Interventions
DRUG

Placebo

Placebo tablet, taken once daily

DRUG

JNJ-38518168

JNJ-38518168, 30 mg tablet, taken once daily

Trial Locations (54)

Unknown

Scottsdale

Los Angeles

Mission Viejo

San Diego

Denver

Waterbury

Minneapolis

St Louis

Bellevue

Lebanon

Rochester

Greenville

Winston-Salem

Cincinnati

Cleveland

Medford

Portland

Altoona

Dallas

San Antonio

Calgary

Vancouver

Hamilton

Kingston

Ottawa

Toronto

Montreal

Québec

Sainte-Foy

Montpellier

Berlin

Frankfurt

Großhansdorf

Hanover

Koblenz

Leipzig

Lübeck

Magdeburg

Mainz

Rüdersdorf

Ashkelon

Haifa

Jerusalem

Ramat Gan

Rehovot

Tel Aviv

Chertsey

Cottingham

Dundee

Glasgow

London

Portsmouth

Southampton

Wolverhampton

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01823016 - A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma | Biotech Hunter | Biotech Hunter